Insulet Announces Changes to Board of Directors with Retirements and New Appointments
January 18 2024 - 4:01PM
Business Wire
Flavia Pease and Timothy Stonesifer to join
Board of Directors
Shacey Petrovic and Corinne Nevinny to
retire from the Board at the Company’s 2024 Annual Meeting
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the
global leader in tubeless insulin pump technology with its Omnipod®
brand of products, today announced the following appointments to
the Company’s Board of Directors, effective January 18:
- Flavia Pease, Corporate Executive Vice President and Chief
Financial Officer at Charles River Laboratories
- Timothy Stonesifer, Chief Financial Officer at Alcon Inc.
In addition, the Company announced Shacey Petrovic and Corinne
Nevinny will retire from the Board during the Company’s 2024 Annual
Meeting in May.
“We are excited to welcome Flavia and Tim to the Insulet Board,”
said Timothy Scannell, Chairman of Insulet’s Board of Directors.
“They are both highly respected leaders who have had distinguished
careers and critical leadership roles in prominent corporations.
Their skills should support and enhance our commitment to
excellence and innovation. We look forward to benefitting from
their expertise and insights.”
Ms. Pease has extensive industry expertise and has managed
finance organizations of expanding, large-scale businesses. She
joined Charles River in 2022 as Corporate Executive Vice President
and Chief Financial Officer where she leads the Finance and
Procurement Functions. Prior to joining Charles River, Ms. Pease
served in a variety of leadership roles at Johnson & Johnson
over her 23-year tenure, including Vice President and Group Chief
Financial Officer of Johnson & Johnson’s global Medical Devices
business, and Vice President, Finance for Janssen North America.
Ms. Pease holds a Bachelor of Science in Economics from the
Pontifícia Universidade Católica in Rio de Janeiro, Brazil, and a
Master of Business Administration from Santa Clara University.
Mr. Stonesifer is a seasoned executive with over 30 years of
global financial and operational experience. He has been the Chief
Financial Officer at Alcon Inc. since April 2019. Prior to joining
Alcon, he served as Executive Vice President and Chief Financial
Officer at Hewlett Packard Enterprise (HPE) from November 2015
through September 2018. Before joining HPE, he served as Chief
Financial Officer of General Motors’ International Operations from
2011 to 2014. Earlier in his career, Mr. Stonesifer served in a
number of chief financial officer roles at divisions of General
Electric during his 21-year tenure. Mr. Stonesifer holds a Bachelor
of Arts in Economics from the University of Michigan.
Ms. Petrovic, who has nearly six years of distinguished Board
service, joined Insulet in 2015 as Chief Commercial Officer and
served as President and Chief Executive Officer for over three
years. Ms. Nevinny is retiring from the Board after five years of
distinguished service.
“As we say goodbye to Shacey Petrovic and Corinne Nevinny, we
thank them for their invaluable contributions and dedication to
Insulet’s mission to improve the lives of people with diabetes,”
continued Mr. Scannell. “Shacey’s time with us is marked by her
visionary and inspiring leadership, which has been instrumental to
our growth trajectory. Her legacy, combined with Corinne’s
significant insights and contributions, leaves an incredibly
positive mark on our Company’s journey, inspiring us to continue
pushing boundaries and achieving new milestones.”
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Massachusetts, is an innovative medical device company dedicated to
simplifying life for people with diabetes and other conditions
through its Omnipod product platform. The Omnipod Insulin
Management System provides a unique alternative to traditional
insulin delivery methods. With its simple, wearable design, the
disposable Pod provides up to three days of non-stop insulin
delivery, without the need to see or handle a needle. Insulet’s
flagship innovation, the Omnipod 5 Automated Insulin Delivery
System, is a tubeless automated insulin delivery system, integrated
with a continuous glucose monitor to manage blood sugar with no
multiple daily injections, zero fingersticks, and can be fully
controlled by a compatible personal smartphone or the Omnipod 5
Controller. Insulet also leverages the unique design of its Pod by
tailoring its Omnipod technology platform for the delivery of
non-insulin subcutaneous drugs across other therapeutic areas. For
more information, please visit insulet.com and omnipod.com.
©2024 Insulet Corporation. Omnipod is a registered trademark of
Insulet Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240118341898/en/
Investor Relations: Deborah R. Gordon Vice President,
Investor Relations (978) 600-7717 dgordon@insulet.com
Media: Angela Geryak Wiczek Senior Director, Corporate
Communications (978) 932-0611 awiczek@insulet.com
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Apr 2024 to May 2024
Insulet (NASDAQ:PODD)
Historical Stock Chart
From May 2023 to May 2024